Analysts Have Conflicting Sentiments on These Technology Companies: Amdocs (DOX), Health In Tech, Inc. Class A (HIT) and Dynatrace (DT)
Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Amdocs (DOX), Health In Tech, Inc. Class A (HIT) and Dynatrace (DT).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amdocs (DOX)
In a report released yesterday, George Notter from Wolfe Research maintained a Hold rating on Amdocs. The company’s shares closed last Thursday at $60.60.
According to TipRanks.com, Notter is a 5-star analyst with an average return of
Currently, the analyst consensus on Amdocs is a Moderate Buy with an average price target of $74.50, implying a 24.3% upside from current levels. In a report released yesterday, TipRanks – DeepSeek also reiterated a Hold rating on the stock with a $69.00 price target.
See today’s best-performing stocks on TipRanks >>
Health In Tech, Inc. Class A (HIT)
In a report released today, Allen Klee from Maxim Group reiterated a Buy rating on Health In Tech, Inc. Class A, with a price target of $4.00. The company’s shares closed last Thursday at $1.41, close to its 52-week low of $0.59.
According to TipRanks.com, Klee is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Health In Tech, Inc. Class A is a Moderate Buy with an average price target of $4.00, a 159.7% upside from current levels. In a report issued on May 2, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $1.50 price target.
Dynatrace (DT)
Goldman Sachs analyst Matthew Martino maintained a Buy rating on Dynatrace yesterday and set a price target of $45.00. The company’s shares closed last Thursday at $34.90.
According to TipRanks.com, Martino is a 2-star analyst with an average return of
Dynatrace has an analyst consensus of Strong Buy, with a price target consensus of $45.00, implying a 29.6% upside from current levels. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $39.00 price target.
Read More on DOX:
Disclaimer & DisclosureReport an Issue
- Amdocs price target lowered to $71 from $88 at Stifel
- Amdocs Posts Solid Q2 2026 Results and Names New CFO as It Pushes Into ‘Agentic’ Telco Era
- Amdocs enters multi-year agreement with Telefonica Moviles Argentina
- Amdocs reports Q2 EPS $1.78, consensus $1.76
- Amdocs sees Q3 EPS $1.81-$1.87, consensus $1.89
